Rhumbline Advisers Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Rhumbline Advisers raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% during the second quarter, Holdings Channel reports. The fund owned 421,320 shares of the pharmaceutical company’s stock after buying an additional 2,799 shares during the period. Rhumbline Advisers’ holdings in Vertex Pharmaceuticals were worth $54,296,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. Private Advisor Group LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.8% in the first quarter. Private Advisor Group LLC now owns 5,328 shares of the pharmaceutical company’s stock valued at $607,000 after buying an additional 94 shares during the last quarter. Princeton Alpha Management LP acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $383,000. Teachers Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 48.6% in the first quarter. Teachers Advisors LLC now owns 510,373 shares of the pharmaceutical company’s stock valued at $55,809,000 after buying an additional 166,998 shares during the last quarter. Dynamic Capital Management Ltd boosted its stake in shares of Vertex Pharmaceuticals by 53.8% in the first quarter. Dynamic Capital Management Ltd now owns 39,614 shares of the pharmaceutical company’s stock valued at $4,332,000 after buying an additional 13,853 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of Vertex Pharmaceuticals by 27.4% in the first quarter. Swiss National Bank now owns 878,809 shares of the pharmaceutical company’s stock valued at $96,098,000 after buying an additional 189,000 shares during the last quarter. Institutional investors and hedge funds own 93.13% of the company’s stock.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 0.88% on Friday, hitting $149.85. 92,546 shares of the stock traded hands. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.86. The company has a market cap of $37.78 billion, a PE ratio of 143.95 and a beta of 1.77. The firm’s 50 day moving average is $143.33 and its 200-day moving average is $114.93.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.33. The firm had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. During the same period last year, the company earned $0.24 EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Rhumbline Advisers Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/11/rhumbline-advisers-increases-position-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html.
Several equities analysts have recently weighed in on VRTX shares. Cowen and Company reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Jefferies Group LLC started coverage on shares of Vertex Pharmaceuticals in a report on Monday, July 10th. They set a “buy” rating and a $155.00 target price for the company. Credit Suisse Group lifted their target price on shares of Vertex Pharmaceuticals from $125.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, July 19th. Barclays PLC reaffirmed an “equal weight” rating and set a $100.00 target price (up from $90.00) on shares of Vertex Pharmaceuticals in a report on Sunday, April 23rd. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $102.62 target price for the company. in a report on Tuesday, May 16th. Five equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $162.88.
In other news, CMO Jeffrey Chodakewitz sold 573 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $129.85, for a total value of $74,404.05. Following the transaction, the chief marketing officer now directly owns 123,084 shares of the company’s stock, valued at approximately $15,982,457.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul M. Silva sold 2,577 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $133.36, for a total value of $343,668.72. Following the completion of the transaction, the senior vice president now directly owns 22,648 shares in the company, valued at $3,020,337.28. The disclosure for this sale can be found here. Insiders sold a total of 751,042 shares of company stock worth $113,078,257 over the last ninety days. Corporate insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.